Mathematical Model of the Brain May Identify Gene Changes Responsible for Cognitive Decline in Aging
May 24th 2021According to the study authors, this model provides insights into the multiscale biological alterations in the elderly and neurodegenerative brain, which have important implications for identifying treatment targets for Alzheimer disease.
Read More
The Value of the Pharmacist in Supporting Patients' Health, Wellness
May 21st 2021Guillermo Rodriguez Navarrete, the founder and CEO of Nutrillermo, and Elaine Ladd, the chief pharmacy officer of Pharmacy Development Services (PDS), discuss the value of the pharmacist in the health and wellness space for patients.
Watch
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer
May 21st 2021In a trial of amivantamab-vmjw, investigators found an overall response rate of 40% among patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 20 insertion mutations.
Read More
The Future of Lengthening the Patient Lifecycle and Further Developing Pharmacy Services
May 21st 2021Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about the future of lengthening the patient lifecycle and further developing pharmacy services.
Watch
Study Shows Cancer Vaccine May Boost Immunotherapy Effectiveness
May 21st 2021The investigators found that using the vaccine in combination with an immune checkpoint inhibitor—an established immunotherapy drug with a 20% success rate overall for patients—can vastly improve the proportion of individuals who respond to treatments, eliminating tumors in 75% of cases in mice.
Read More
Is Now the Right Time for Pharmacy to Expand into the Health, Wellness Space?
May 21st 2021Guillermo Rodriguez Navarrete, the founder and CEO of Nutrillermo, and Elaine Ladd, the chief pharmacy officer of Pharmacy Development Services (PDS), discuss whether the shift in the public's awareness of the critical role of the pharmacist during the pandemic could support pharmacists’ move to a more significant role in the health and wellness space.
Watch
Topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP), found that the study did not meet its primary endpoint of demonstrating a statistically significant improvement in the proportion of treated study eyes.
Read More